Verastem, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing drugs to improve outcomes for patients with cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. Its lead FAK inhibitor is defactinib (VS-6063), an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds. The company's defactinib is in Phase 1b study for the treatment of pancreatic cancer, as well as in Phase 1/2 clinical trial for the treatment of ovarian cancer, non-small cell lung cancer, mesothelioma, and pancreatic cancer. It also engages in developing duvelisib, an investigational oral therapy that targets the PI3K signaling pathway, as well as attacks malignant B-cells and T-cells and disrupt the tumor microenvironment to help thwart their growth and proliferation for patients with lymphatic cancers through the dual inhibition of PI3K delta and gamma.
| Revenue (Most Recent Fiscal Year) | $0.01M |
| Net Income (Most Recent Fiscal Year) | $-130.64M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -1486.92% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -2003.62% |
| Return on Assets (Trailing 12 Months) | -127.97% |
| Current Ratio (Most Recent Fiscal Quarter) | 3.50 |
| Quick Ratio (Most Recent Fiscal Quarter) | 3.50 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 2.77 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $-0.65 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.96 |
| Earnings per Share (Most Recent Fiscal Year) | $-3.66 |
| Diluted Earnings per Share (Trailing 12 Months) | $-3.20 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 54.95M |
| Free Float | 53.80M |
| Market Capitalization | $250.57M |
| Average Volume (Last 20 Days) | 2.33M |
| Beta (Past 60 Months) | 0.85 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 2.10% |
| Percentage Held By Institutions (Latest 13F Reports) | 88.37% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |